Delcath Announces Acceptance of Abstract for Oral Presentation at ECIO 2019
February 08, 2019 08:00 ET | Delcath Systems, Inc.
NEW YORK, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Announces Enrollment of First Patient in ALIGN Trial
October 18, 2018 08:00 ET | Delcath Systems, Inc.
The University of Tennessee Health Science Center, Methodist University Hospital, and West Cancer Center Begin Treatments in New Registration Trial for Intrahepatic Cholangiocarcinoma NEW YORK, Oct. ...
Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC Published in European Radiology
October 04, 2018 08:00 ET | Delcath Systems, Inc.
NEW YORK, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC to be Published in European Radiology
September 04, 2018 08:00 ET | Delcath Systems, Inc.
NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Announces Initiation of Registrational Trial of Melphalan/HDS in Intrahepatic Cholangiocarcinoma
May 07, 2018 08:00 ET | Delcath Systems, Inc.
NEW YORK, May 07, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that...
ASLAN Pharmaceuticals Sponsors Cholangiocarcinoma Foundation Annual Conference 2018
January 31, 2018 01:00 ET | ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Jan. 31, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN) (6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...
Persistence Market Research.jpg
Bile Duct Cancer (Cholangiocarcinoma) Treatment Market to show Incremental Opportunity of US$ 144.2 Mn by 2025 - Persistence Market Research
December 21, 2017 03:32 ET | Persistence Market Research
New York City, NY, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Persistence Market Research(PMR) forecasts the global bile duct cancer treatment market to grow from about US$ 168 Mn in 2017 to about US$ 312 Mn...
ArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer
June 30, 2016 07:00 ET | ArQule, Inc.
75% disease control rate, including a 25% objective response rate, was observed in 12 evaluable patients harboring FGFR2 genetic alterations BURLINGTON, Mass., June 30, 2016 (GLOBE NEWSWIRE) --...
ArQule to Present Preliminary Phase 1/2 Data for FGFR Inhibitor, ARQ 087, in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer
June 23, 2016 07:00 ET | ArQule, Inc.
BURLINGTON, Mass., June 23, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that preliminary data from the ongoing phase 2 portion of a phase 1/2 trial in intrahepatic...
ArQule Reports Fourth Quarter and Full Year 2015 Financial Results
February 29, 2016 07:00 ET | ArQule, Inc.
Conference Call Scheduled Today at 9:00 a.m. ET BURLINGTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced its financial results for the fourth quarter and...